Stoke Therapeutics (STOK) Equity Average (2018 - 2026)

Stoke Therapeutics has reported Equity Average for 9 years, with the latest figure at $373.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 29.05% year-over-year to $373.7 million; the trailing twelve-month figure through Mar 2026 stood at $373.7 million (up 29.05% YoY), and the FY2025 full-year result was $290.7 million, up 49.64% from the prior year.
• Equity Average for Q1 2026 stood at $373.7 million, up from $330.3 million in the prior quarter.
• The five-year high for Equity Average was $373.7 million in Q1 2026, with the low at $150.0 million in Q1 2024.
• Average Equity Average over 5 years is $240.4 million, with a median of $228.9 million recorded in 2022.
• Year-over-year, Equity Average dropped 24.77% in 2024 and surged 93.09% in 2025.
• Tracing STOK's Equity Average over 5 years: stood at $194.5 million in 2022, then slipped by 14.51% to $166.3 million in 2023, then jumped by 38.66% to $230.6 million in 2024, then soared by 43.25% to $330.3 million in 2025, then increased by 13.14% to $373.7 million in 2026.
• The last three Equity Average figures came in at $373.7 million (Q1 2026), $330.3 million (Q4 2025), and $321.5 million (Q3 2025), per Business Quant data.

Peer Comparison